EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration.

2025.08.13

Date

Title

2019-12-12

Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1

2019-08-21

Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List

2019-08-12

Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million

2019-08-02

Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment

2019-07-19

Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea

2019-05-15

Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index

2019-04-29

Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting

2019-03-12

FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT